The European Medicines Agency (EMA) has authorized Moderna’s third dose of Covid-19 vaccine for immunocompromised individuals aged 12 years and older. This was announced by the pharmaceutical company. The EMA has therefore authorized the third dose of the Moderna Covid-19 vaccine (Spikevax) administered at least 28 days after the second dose to severely immunocompromised individuals aged 12 years or older.
Covid, the Moderna vaccine 95 percent effective in preventing hospitalizations
by Priscilla Di Thiene
A growing number of studies, the company notes in a statement, have demonstrated the benefit of a third dose of the Covid-19 vaccine in immunocompromised individuals. In particular, a recent double-blind study of 120 subjects undergoing solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, pancreas) showed that a third dose of the Moderna Covid-19 vaccine improved immune response compared to placebo. In the study, the third dose was generally well tolerated.
Covid vaccine, the adverse effects of the third dose comparable to those of the second
The head of the vaccination strategy of the European Medicines Agency Marco Cavaleri he announced that the administration of a booster dose of the Comirnaty vaccine is part of the “application of vaccination strategies in EU countries”, which “remains the responsibility of the national authorities”.
The booster dose “can be taken into consideration”, he added, but “no recommendation can be made at the moment about the timing and who to use it” beyond the preliminary indications provided yesterday. The booster six months after the second dose for the population aged 18 to 55 “is safe”.